News

Polypill-based therapy likely to reduce ethnic inequities in use of cardiovascular preventive medications

April 10 2017

New Zealand research has demonstrated that a cardiovascular polypill can improve adherence to medicines proven to improve survival. Medicines are only effective if we take them although in New Zealand only a fraction of people that have suffered a cardiovascular event (heart attack or stroke) take the medicines proven to make them live longer. This […]

Read More

World Health Organisation considers Trinomia® as an Essential Medicine

March 13 2017

Trinomia®,the first cardiovascular polypill, is being considered by the WHO as an Essential Medicine.   Inclusion on the Essential Medicines List (EML) allow access and funding for poor, lower and middle income countries. Supporters of the application including institutes such as Oxford University, the University of Auckland, Harvard Medical School and the World Heart Federation […]

Read More

World Health Organisation (WHO) Evaluating Microdacyn For World Essential Medicines List

March 6 2017

The World Health Organisation (WHO) has accepted for review the first ever New Zealand based submission for a product entry on the Essential Medicines List.   The World Health Organisation (WHO) Essential Medicines List (EML) committee considers Microdacyn technology during April. Microdacyn is a super oxidised solution used to prevent and manage infection while clinically […]

Read More

Microdacyn Leads The Way In New International Guidelines

January 15 2017

Microdacyn wound care solution has been included in the new International Wound Infection Institute (IWII) clinical practice Guidelines.   The IWII is a multidisciplinary international group of experts dedicated to sharing the latest developments in wound infection and infection prevention. The guidelines have a focus on biofilm and wound infection.   Microdacyn is newly included […]

Read More

UroFem receives ACC approval

September 30 2016

UroFem 1000mg d-mannose tablets are now an approved product, meaning UroFem is funded for people eligible under Accident Compensation Corporation (ACC).   Urinary Tract Infections (UTIs) affect a large number of people that have received an accident related injury, including trauma and burns. People most affected include those with a spinal cord injury and those that […]

Read More

Heart Failure Medicine approval for Te Arai BioFarma

August 22 2016

A Medicine which is currently not available to New Zealanders through PHARMAC received Medsafe regulatory approval this week. Eplerenone Te Arai (eplerenone) is used as an adjunct in the management of chronic heart failure. Eplerenone has been well studied and demonstrates a significant survival benefit in people that have heart failure after a heart attack. […]

Read More

Te Arai BioFarma partners with Dipharma for high needs Medicines

August 8 2016

Te Arai BioFarma and International pharmaceutical company Dipharma have partnered to bring high need Medicines to New Zealand.   The agreement begins with the registration and supply of three high needs Medicines. The Medicines are for  rare conditions such as metabolic disorders that have serious consequences on quality of life and can reduce life expectancy.   “With […]

Read More

Green Cross Health pharmacies to range Microdacyn

July 30 2016

The largest pharmacy group in New Zealand Green Cross Health, has made the decision to have Microdacyn as a core ranged product within their pharmacy first aid section. “Microdacyn is a unique product for skin damage and acute wounds. Ideally people want a powerful local antimicrobial effect to prevent infection but also want to enable […]

Read More

Te Arai BioFarma continues environmental restoration

April 13 2016

For many years the Gravatt family has taken to the restoration of native forest at the headwater of the Waitapu Stream. The stream is the eastern most tributary of the Kaipara Harbour and the area is adjacent to a Department of Conservation (DOC) reserve. Previously grassed, unloved farmland the gullys are now home to a […]

Read More

Clinical trials of D-mannose aid Antimicrobial Stewardship in New Zealand

April 13 2016

Until recently there has been a paucity of randomised controlled trials (RCTs) in relation to the non-antibiotic improvement of UTI symptoms and maintenance of a healthy Urinary tract and bladder.   Like other countries New Zealand has experienced steep growth in the  incidence of drug resistant urinary tract issues, making effective management with antibiotics difficult. […]

Read More

Older posts